Leo sues Perrigo for patent infringement over skin gel

Leo Pharma has filed suit against Perrigo in the US District Court for the District of Delaware alleging patent infringement.

This filing of the suit, on June 10, follows Perrigo’s filing of Abbreviated New Drug Applications with the US Food and Drug Administration for ingenol mebuttae gel (0.015% and 0.05%), which are generic versions of Leo’s Picato gel.

Leo’s filing of the suit started the litigation process under the Hatch-Waxman Act.

Picato is a prescription medication for treatment of actinic keratosis, which is a skin condition from overexposure to the sun.

In a statement, Perrigo’s CEO, John Hendrickson, said: “This filing illustrates Perrigo’s commitment to providing quality affordable healthcare products”.